Selected article for: "acute pneumonia and low molecular weight heparin"
Author: Poggiali, Erika; Bastoni, Davide; Ioannilli, Eva; Vercelli, Andrea; Magnacavallo, Andrea
Title: Deep Vein Thrombosis and Pulmonary Embolism: Two Complications of COVID-19 Pneumonia?
  • Cord-id: ie9dn724
  • Document date: 2020_4_8
    • ID: ie9dn724
    Snippet: Coronavirus disease 19 (COVID-19) is a worldwide infection which was recently declared a global health emergency by the WHO Emergency Committee. The most common symptoms are fever and cough, which can progress to pneumonia, acute respiratory distress syndrome (ARDS) and/or end-organ failure. Risk factors associated with ARDS and death are older age, comorbidities (e.g., hypertension, diabetes, hyperlipidaemia), neutrophilia, and organ and coagulation dysfunction. Disseminated intravascular coagu
    Document: Coronavirus disease 19 (COVID-19) is a worldwide infection which was recently declared a global health emergency by the WHO Emergency Committee. The most common symptoms are fever and cough, which can progress to pneumonia, acute respiratory distress syndrome (ARDS) and/or end-organ failure. Risk factors associated with ARDS and death are older age, comorbidities (e.g., hypertension, diabetes, hyperlipidaemia), neutrophilia, and organ and coagulation dysfunction. Disseminated intravascular coagulation and coagulopathy can contribute to death. Anticoagulant treatment is associated with decreased mortality in severe COVID-19 pneumonia. In this report we describe two patients with COVID-19 pneumonia who developed venous thromboembolism. LEARNING POINTS: Deep vein thrombosis and pulmonary embolism can occur in patients with COVID-19 pneumonia. Low-molecular-weight heparin prophylaxis does not decrease the risk of venous thromboembolism (VTE) in COVID-19 pneumonia. In the presence of clinical signs and/or suspicion of VTE, compression ultrasound and echocardiography should be always performed, irrespective of disease stage.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and long period: 1, 2
    • acute ards respiratory distress syndrome and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute ards respiratory distress syndrome and low positive: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute renal failure and long period: 1
    • acute renal failure and low molecular weight: 1, 2, 3
    • acute renal failure and low positive: 1
    • lmwh administration and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8
    • lmwh hydroxychloroquine and low molecular weight: 1, 2, 3
    • lmwh mainly low molecular weight heparin and low molecular weight: 1, 2, 3, 4
    • lmwh therapy and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • long period and low positive: 1, 2, 3, 4